Category Archives: Parkinson’s Treatment

23-04-2012 08:05 Chief of neurosurgery G. Rees Cosgrove, MD, discusses the signs and symptoms of Parkinson's Disease and treatment options. Learn more about neurosciences at Rhode Island Hospital: Link: Treating Parkinson's Disease at Rhode Island Hospital - Video … Continue reading →

TORONTO, ONTARIO--(Marketwire -04/23/12)- Cynapsus Therapeutics (TSX-V: CTH.V - News), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced that it has appointed Dr. Abraham Lieberman to its Clinical Advisory Board (CAB). Dr. Lieberman is the Director of the Muhammad Ali Parkinson Center and Movement Disorder Clinic of the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center. The news follows completion of the Company's first human clinical study of APL- 130277, a reformulation of an approved drug (Apomorphine), for the treatment of motor fluctuation in Parkinson's disease. The new appointment enhances the range and depth of expertise of the CAB, which provides medical, clinical and strategic guidance for the Company's product development and commercialization activities. "Cynapsus is very pleased to have Dr. Lieberman join our Clinical Advisory Board. His vast knowledge and commitment to improving treatments and outcomes for Parkinson's patients will be especially valuable as we advance APL -130277 towards clinical practice," said Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus. "Dr. Lieberman joins an international group of Clinical Advisory Board members, including Dr. Warren Olanow and Dr. Fabrizio Stocchi. Collectively their experience … Continue reading →

Kolkata, Apr 24 : Pharmaceutical and biotechnology major Wockhardt has launched an authorized generic version of four strengths (50mg, 75mg, 125mg and 200mg) of the triple-drug combination product containing Levodopa, Carbidopa and Entacapone, which are used in treatment of Parkinsons disease. The Levodopa + Carbidopa + Entacapone tablet is the generic name for the brand Stalevo, owned by Orion Corporation and marketed in the United States by Novartis. Wockhardt launched the product on Monday and is entitled to 180-days of exclusivity. Wockhardt was the first-to-file with paragraph-IV certification on four out of six strengths of this product, said Wockhardt Chairman Dr. Habil Khorakiwala. Pursuant to a settlement of the litigation between Wockhardt and Orion Corporation, Finland, the holder of the NDA, Wockhardt came to an arrangement to launch an authorized generic version with 180-days of exclusivity. The product involved development of a complex API as well as a triple-drug combination formulation, he said. Incidence of Parkinsons disease is increasing worldwide. According to IMS Health, the total market for this product in the US is about USD 55 million for the above four strengths and even after the 180-days exclusivity the number of competitors to enter the market is expected to … Continue reading →

New Delhi, Apr 24: Wockhardt said on Tuesday that it has launched a generic version of Orion Corporations Parkinsons treatment drug Stalevo in the US, with 180 days of marketing exclusivity. The company said its generic copy is of four strengths (50mg, 75mg, 125mg and 200mg) of the triple drug combination product containing levodopa, carbidopa and entacapone. Wockhardt was the firsttofile with paragraph IV certification on four out of six strengths of this product, Wockhardt Chairman, Mr Habil Khorakiwala, said in a statement. Pursuant to a settlement of the litigation between Wockhardt and Orion Corporation, Finland, the two parties came to an arrangement to launch an authorised generic version with 180 days of exclusivity, he added. Wockhardt launched the product on April 23, 2012 and is entitled to 180 days of exclusivity, the company said. The combination of levodopa, carbidopa and entacapone tablet is the generic name for the brand Stalevo, owned by Orion Corporation and marketed in the US by Novartis. Citing IMS Health, Wockhardt said the total market for this product in the US is about $ 55 million for the above four strengths and even after the 180 days exclusivity the number of competitors to enter the … Continue reading →

- Fox Foundation to sponsor a clinical trial to study Sanofi compound - PARIS , France , April 19, 2012 /CNW Telbec/ - Sanofi (EURONEXT: BSAC - News) (NYSE: SNY - News) announced today that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor - phosphodiesterase type 4 inhibitor - in patients with Parkinson's disease (PD). "AVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease, an area of unmet need where a new treatment could make a tangible difference in patients' lives," said Todd Sherer , Ph.D., Chief Executive Officer of MJFF. "Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation's approach and help us speed scientific advances with potential to improve the treatment of Parkinson's for patients today and in the future." Under the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinson's disease. All data and results generated by the clinical … Continue reading →

Despite researchers' best efforts, Parkinson's disease remains incurable. While there are treatment options that mitigate some symptoms, assigning the right treatment approach can be hit or miss. To better predict the response of Parkinson's patients to therapy, the Cleveland Clinic has joined consumer genomics company 23andMe in its Parkinson's Community Research Project. Enrollment in the program will also allow the clinic's patients to take advantage of 23andMe's Personal Genome Service. 23andMe began its Parkinson's disease collaboration in 2009 when it teamed up with the Michael J. Fox Foundation for Parkinson's Research and the Parkinson's Institute and Clinical Center. After roughly 18 months, the collaboration had assembled and analyzed genetic data from more than 3,400 Parkinson's patients, found 20 previously known genetic associations, and identified two novel loci rs6812193 near SCARB2 and rs11868035 near SREBF1/RA11. Ultimately, the collaboration aims to enroll 10,000 people. To date, 23andMe has enrolled roughly 6,500 patients, and the Cleveland Clinic is planning to add another 1,000 patients. For clinicians like Andre Machado, director of the Cleveland Clinic's Center for Neurological Restoration, the ideal scenario is that this large-scale collaboration can produce a roadmap to advance treatments for Parkinson's patients. "We're hoping to get data on the … Continue reading →

BY JOHN R. LUCIANO Its a progressively debilitating disease that affects 1 million people living in the United States today, according to the Parkinsons Disease Foundation. There is no known cure, and those suffering with it can expect serious changes to their life style, freedom of movement and quality of life. Yet despite the daunting challenges that face him, one Jefferson Township resident who is combating this condition does it with humor and courage, and has formed a team around him to help raise money to find a cure. PHOTO/JOHN R. LUCIANO Jefferson resident Skeets Sturtevant, posing with daughter Lauren Geaney and grandson Jack, has been battling Parkinsons Disease for over 10 years. His family formed 'Feets For Skeets,' a team that participates in the Unity Walk. "I sometimes find myself taking a trip down the stairswithout the stairs," said Skeets Sturtevant, 65, who has dealt with Parkinsons since at least 1998. "Some people with this disease lose their sense of humor. I use mine to fight it." Admittedly his jokes dont always go over well, but that doesnt stop him. That source of strength has helped garner him support from his family, friends and church in Jefferson. It also … Continue reading →

TORONTO, ONTARIO--(Marketwire -03/28/12)- Attention: Health and Lifestyle Editors This April, Parkinson's Awareness Month, Parkinson Society Canada wants the Canadian public to know that a Parkinson disease diagnosis is a call to take control, find answers and stay informed. More than 100,000 Canadians are living with Parkinson's. While the symptoms of Parkinson's disease affect each individual differently, whether it is walking, eating, or getting dressed to go to work, everything takes more time, and can cause frustration. There are steps individuals can take to keep their symptoms from progressing too quickly. "Rather than waiting for a drug to come out and help us, exercise is something we can do, at this very moment, to take care of ourselves," says Linda Jean Remmer, 62, diagnosed in December 2009. Linda Jean says being active makes her feel better, knowing she is doing something. "It gives me hope." Parkinson's is a chronic degenerative neurological disease caused by a loss of dopamine in the brain. It affects over 100,000 Canadians. There is no cure. Symptoms include: resting tremor, slowness of movement, stiffness or rigidity of muscles, difficulty with balance and walking, changes in voice volume and speech, and difficulty with fine movements. Non-motor symptoms include … Continue reading →

TORONTO, ONTARIO--(Marketwire - March 26, 2012) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH.V - News), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced its results for the fourth quarter and fiscal year ended December 31, 2011. Unless specified otherwise, all amounts are in Canadian dollars. "2011 was a successful year for Cynapsus with achievement of multiple significant milestones. In particular, the year was highlighted by the completion of the first human clinical trial for APL-130277, the announcement of findings from a global neurologist survey confirming market need for APL-130277, and the completion of the acquisition of Adagio Pharmaceuticals," said Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus. "Building on this success, we remain focused on the completion of a dose escalation study in the next 3 to 4 months, as well as preparations for an Investigational New Drug Application to the US FDA for a clinical BioEquivalence study later in the year. The BEQ study is the next critical de-risking milestone that we believe will drive significant shareholder value." Financial Highlights Operational Highlights The following achievements were made during the year: Cynapsus Completed the First … Continue reading →

Public release date: 26-Mar-2012 [ | E-mail | Share ] Contact: Megan McCann memccann@nmh.org 312-926-5900 Northwestern Memorial Hospital CHICAGO For nearly 30 years, Tom Rogers' left hand would shake when he tried to use it, making even simple tasks such as drinking a glass of water, writing a check, or making a sandwich challenging. The tremor eventually became so disruptive that he lost use of his dominant hand. Rogers sought care and learned that his tremor was a symptom of Parkinson's disease, yet felt he was suffering from something different. "I was familiar with Parkinson's because my father had it and I knew this wasn't the same," said Rogers, a 66-year-old retired truck driver who resides in Oswego, Ill. "It was exactly the opposite of my dad's tremor which would start when he was still or relaxed. My hand would shake when I had something in it or tried to use it." Also convinced that her husband was suffering from something other than Parkinson's, Pam Rogers began searching the internet. Through her research the couple learned about another movement disorder called essential tremor and found their way to Northwestern's Parkinson's Disease and Movement Disorders Center. Northwestern Medicine movement disorder specialists … Continue reading →